Multidrug Resistent BacteriaNCT04431440
Silver Nanoparticles in Multidrug Resistant Bacteria
An observational study of Multidrug Resistent Bacteria, run by Assiut University at 1 site in Egypt.
Trial summary
Recently, silver nanoparticles (AgNPs) have been widely used in various applications as antimicrobial agents, anticancer, diagnostics, biomarkers, cell labels, and drug delivery systems for the treatment of various diseases. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Multidrug Resistent Bacteria
- What is being tested?
- silver nanoparticles
- How many people
- 150 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jun 2020to 13 Oct 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: critically ill patients
Who may be able to join
- Intensive care patients
Who cannot join
- none
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Bactericidal Effect of Silver Nanoparticles on Methecillin and Vancomycin Resistant Staphylococcus. Aureus (MRSA) Isolated From Critically Ill Patients
Recently, silver nanoparticles (AgNPs) have been widely used in various applications as antimicrobial agents, anticancer, diagnostics, biomarkers, cell labels, and drug delivery systems for the treatment of various diseases. The present study investigated the bactericidal effect of AgNPs against Methecillin Resistant Staph. aureus (MRSA) and Vancomycin resistant Staph aureus (VRSA)
- Conditions
- Multidrug Resistent Bacteria
- Being tested
- silver nanoparticles
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
silver nanoparticlesOther
effect silver nanoparticles will be examined on multidrug resistant bacteria
| Study group | Role | What they receive |
|---|---|---|
| Methicillin resistant staphylococcus aureus | Not described Receives: Other: silver nanoparticles | |
| vancomycin resistent staphylococcus aureus | Not described Receives: Other: silver nanoparticles |
What is being measured
The primary outcome is the main question the study is designed to answer.
bactericidal effect of silver nanoparticles on multidrug resistant bacteria
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jun 2020
- Study start1 Jun 2020
- Primary completion5 Oct 2020
- Study completion13 Oct 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Multidrug Resistent BacteriaStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rasha Hamed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04431440
- Sponsor's protocol ID
- XXXXX
- Status last verified
- Nov 2020
- First submitted
- 11 Jun 2020
- Last updated
- 5 Nov 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Elsawy S, Elsherif WM, Hamed R. Effect of silver nanoparticles on vancomycin resistant Staphylococcus aureus infection in critically ill patients. Pathog Glob Health. 2021 Jul;115(5):315-324. doi: 10.1080/20477724.2021.1914412. Epub 2021 Apr 19.
PubMed 33872131
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bactericidal Effect of Silver Nanoparticles on Methecillin and Vancomycin Resistant Staphylococcus. Aureus (MRSA) Isolated From Critically Ill Patients
- ClinicalTrials.gov ID
- NCT04431440
- Acronym / sponsor ID
- XXXXX
- Conditions
- Multidrug Resistent Bacteria
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jun 2020 (actual)
- Primary completion
- 5 Oct 2020 (actual)
- Study completion
- 13 Oct 2020 (actual)
- First posted
- 16 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Recently, silver nanoparticles (AgNPs) have been widely used in various applications as antimicrobial agents, anticancer, diagnostics, biomarkers, cell labels, and drug delivery systems for the treatment of various diseases. The present study investigated the bactericidal effect of AgNPs against Methecillin Resistant Staph. aureus (MRSA) and Vancomycin resistant Staph aureus (VRSA)
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Methicillin resistant staphylococcus aureus | – | Other: silver nanoparticles |
| vancomycin resistent staphylococcus aureus | – | Other: silver nanoparticles |
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- critically ill patients
Key inclusion criteria (1 listed)
- Intensive care patients
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| silver nanoparticleseffect silver nanoparticles will be examined on multidrug resistant bacteria | Other | Methicillin resistant staphylococcus aureus, vancomycin resistent staphylococcus aureus |
Primary outcome
bactericidal effect of silver nanoparticles on multidrug resistant bacteria
Time frame: 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2020.
- Derived from this study: PubMed 33872131Elsawy S, Elsherif WM, Hamed R. Effect of silver nanoparticles on vancomycin resistant Staphylococcus aureus infection in critically ill patients. Pathog Glob Health. 2021 Jul;115(5):315-324. doi: 10.1080/20477724.2021.1914412. Epub 2021 Apr 19.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multidrug Resistent Bacteria, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
bactericidal effect of silver nanoparticles on multidrug resistant bacteria (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04431440, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2020.